The DOPPS practice monitor for US dialysis care: Trends through August 2011

American Journal of Kidney Diseases

Volumn 60, Issue 1, 2012, Pages 160-165

  Pisoni, Ronald L ^a   Fuller, Douglas S ^a   Bieber, Brian A ^a   Gillespie, Brenda W ^a   Robinson, Bruce M ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIALYSIS; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; IRON STORAGE; KIDNEY FAILURE; MONITORING; SHORT SURVEY; UNITED STATES;

EID: 84862614926     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.04.001     Document Type: Article

References (5)

1. Robinson BM, Fuller DS, Zinsser D, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis. 2011;57(6):822-831.
2. Robinson BM, Fuller DS, Bieber BA, Turenne MN, Pisoni RL. The DOPPS Practice Monitor for US dialysis care: trends through April 2011. Am J Kidney Dis. 2012;59(2):309-312.
3. US Food and Drug Administration, US Department of Health and Human Services. FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis- stimulating agents (ESAs) in chronic kidney disease (safety announcement 6-24-2011). Available at: http://www.fda.gov/ drugs/drugsafety/ucm259639.htm. Accessed March 2, 2012.
4. Renal Network of the Upper Midwest. Elab Project: National 2010 and Trends Elab Report. Available at: http://www.esrdnet11.org/Elab/elab-national- 2010-and-trends-report.pdf. Accessed February 24, 2012.
5. Ibrahim HN, Skeans MA, Li Q, Ishani A, Snyder JJ. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. Clin Transplant. 2011;25(4):653-659.